Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
VCYT 
Veracyte Inc (VCYT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: VCYT (4-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 30.8% | Avg. Invested days 44 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.30B USD | Price to earnings Ratio 95.35 | 1Y Target Price 44.5 |
Price to earnings Ratio 95.35 | 1Y Target Price 44.5 | ||
Volume (30-day avg) 1062673 | Beta 1.8 | 52 Weeks Range 18.61 - 47.32 | Updated Date 04/1/2025 |
52 Weeks Range 18.61 - 47.32 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.31 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 5.42% | Operating Margin (TTM) 6.62% |
Management Effectiveness
Return on Assets (TTM) 1.39% | Return on Equity (TTM) 2.18% |
Valuation
Trailing PE 95.35 | Forward PE 24.33 | Enterprise Value 2072358489 | Price to Sales(TTM) 5.17 |
Enterprise Value 2072358489 | Price to Sales(TTM) 5.17 | ||
Enterprise Value to Revenue 4.65 | Enterprise Value to EBITDA 42.12 | Shares Outstanding 77944800 | Shares Floating 77565181 |
Shares Outstanding 77944800 | Shares Floating 77565181 | ||
Percent Insiders 0.65 | Percent Institutions 104.98 |
Analyst Ratings
Rating 4.09 | Target Price 43.22 | Buy 2 | Strong Buy 6 |
Buy 2 | Strong Buy 6 | ||
Hold 2 | Sell - | Strong Sell 1 | |
Strong Sell 1 |
Upturn AI SWOT
Veracyte Inc
Company Overview
History and Background
Veracyte Inc. was founded in 2008. It's a genomic diagnostics company focused on improving patient outcomes by providing actionable genomic information to inform clinical decisions.
Core Business Areas
- Genomic Testing: Development and commercialization of genomic tests for various diseases, primarily in pulmonology, thyroid, and urology.
Leadership and Structure
Marc Stapley is the CEO. The company has a typical corporate structure with departments for R&D, Commercial Operations, Finance, and Legal.
Top Products and Market Share
Key Offerings
- Afirma Thyroid FNA Analysis: Genomic test for thyroid nodules to help avoid unnecessary surgeries. Market share is significant in the thyroid nodule assessment market. Competitors include Exact Sciences and smaller regional labs.
- Envisia Genomic Classifier: Helps diagnose idiopathic pulmonary fibrosis (IPF) by analyzing lung tissue samples. No specific market share numbers, but they are considered a major competitor. Competitors include Biodesix and InterMune (acquired by Roche).
- Decipher Prostate Cancer Classifier: Decipher is a genomic test that predicts how likely prostate cancer is to spread. Competitors are GenomeDx and Myriad Genetics.
- Percepta Nasal Swab test: Percepta is a genomic test that helps improve lung cancer detection. Competitors are Biodesix and other genomic testing companies.
Market Dynamics
Industry Overview
The genomic diagnostics industry is growing rapidly, driven by advancements in genomics, increasing demand for personalized medicine, and the need for more accurate diagnostic tests.
Positioning
Veracyte is positioned as a leader in genomic testing for various diseases, with a focus on providing actionable information to improve patient outcomes. Their competitive advantage lies in their proprietary technology and clinical validation of their tests.
Total Addressable Market (TAM)
The total addressable market is estimated in the billions of dollars, across the pulmonology, urology, and thyroid markets. Veracyte is positioned to capture a significant share of this market through its existing products and pipeline.
Upturn SWOT Analysis
Strengths
- Proprietary Genomic Technology
- Strong Clinical Validation
- Established Commercial Infrastructure
- Experienced Management Team
Weaknesses
- Reliance on Reimbursement
- Competition from Larger Players
- Limited Product Portfolio in Some Areas
Opportunities
- Expansion into New Disease Areas
- Strategic Partnerships
- Increased Adoption of Genomic Testing
- International Expansion
Threats
- Changes in Reimbursement Policies
- Emergence of New Competitors
- Technological Advancements by Competitors
- Economic Downturn
Competitors and Market Share
Key Competitors
- ESMO
- EXAS
- CDNA
Competitive Landscape
Veracyte faces competition from larger diagnostic companies with broader product portfolios. However, Veracyte has a competitive advantage in its specialized genomic tests and strong clinical validation.
Major Acquisitions
HalioDx
- Year: 2021
- Acquisition Price (USD millions): 260
- Strategic Rationale: Expanded Veracyte's presence in immuno-oncology and provided access to new technologies and markets.
Growth Trajectory and Initiatives
Historical Growth: Veracyte has experienced revenue growth in recent years, driven by increased adoption of its genomic tests.
Future Projections: Analyst estimates project continued revenue growth for Veracyte, driven by expansion into new markets and increasing adoption of genomic testing.
Recent Initiatives: Recent initiatives include expanding its product portfolio, entering into strategic partnerships, and increasing its sales and marketing efforts.
Summary
Veracyte is a growing genomic diagnostics company with a strong portfolio of tests. Their strengths are their proprietary technology, clinical validation, and focused market. However, they face competition and rely on reimbursements. Future growth depends on expanding into new markets and strategic partnerships.
Similar Companies
CDNA
CareDx Inc
CDNA
CareDx Inc
EXAS
EXACT Sciences Corporation
EXAS
EXACT Sciences Corporation
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Publications
- Company Website
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is estimated and may vary. Financial data is based on publicly available information and may not be complete or accurate. Please conduct thorough due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Veracyte Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2013-10-30 | CEO & Director Mr. Marc A. Stapley | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 824 | Website https://www.veracyte.com |
Full time employees 824 | Website https://www.veracyte.com | ||
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It is also developing the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.